Lu Bin, Yu Ying, Xing Xiao-Ling, Liu Rui-Yue
Department of Otorhinolaryngology and Head and Neck Surgery, The first people's Hospital of Jingzhou, Jingzhou, P.R. China.
E.N.T. department, Gaotang County People's Hospital, Liaocheng, P.R. China.
J Recept Signal Transduct Res. 2022 Apr;42(2):133-140. doi: 10.1080/10799893.2020.1863987. Epub 2020 Dec 27.
Laryngeal cancer (LCa) is a prevalent malignant head and neck cancer with relatively unclear pathogenesis. A prior study has suggested that miR-183 differentially expressed in laryngeal-related malignancies, but its accurate role has not been fully ascertained in LCa. miR-183 expression in LCa tissues and cells was detected assisted by TCGA/GEO databases or qRT-PCR assay, relatively. Target genes of miR-183 were predicted accessing to TargetScan website. Luciferase activity analysis was conducted to determine the relationship between miR-183 and its possible target. CCK-8, colony formation and transwell invasion and migration experiments were implemented to measure LCa cell viability, invasion and migration. Western blot assay was utilized to evaluate cell adhesion and EMT-related proteins expressions. The expression of miR-183 was expressed in LCa tissue samples and cells at higher levels than normal controls. Upregulation of miR-183 facilitated Hep-2 and TU212 cells viability, while miR-183 reduction inhibited the proliferative potential of Hep-2 and TU212 cells. TMSB4Y was determined as a possible target of miR-183, and its expression was decreased in LCa. LCa patients with low TMSB4Y expression had poorer outcomes relative to that with high TMSB4Y expression. TMSB4Y overturned the promoting impacts of miR-183 on the LCa cellular malignant behaviors, including cell proliferation, colonogenicity, invasion and migration. miR-183 overexpression inhibited cell adhesion through inhibiting TMSB4Y expression. Overall, all results elucidated that miR-183, as an oncogenic molecule in LCa, may be used to predict the prognosis of LCa patients by targeting TMSB4Y.
喉癌(LCa)是一种常见的头颈部恶性肿瘤,其发病机制相对不明。先前的一项研究表明,miR-183在喉相关恶性肿瘤中表达存在差异,但其在喉癌中的准确作用尚未完全明确。分别借助TCGA/GEO数据库或qRT-PCR检测喉癌组织和细胞中miR-183的表达。通过访问TargetScan网站预测miR-183的靶基因。进行荧光素酶活性分析以确定miR-183与其可能的靶标之间的关系。实施CCK-8、集落形成以及Transwell侵袭和迁移实验来检测喉癌细胞的活力、侵袭和迁移能力。利用蛋白质免疫印迹法评估细胞黏附及与上皮-间质转化(EMT)相关的蛋白表达。miR-183在喉癌组织样本和细胞中的表达水平高于正常对照。miR-183的上调促进了Hep-2和TU212细胞的活力,而miR-183的降低则抑制了Hep-2和TU212细胞的增殖潜能。TMSB4Y被确定为miR-183的一个可能靶标,其在喉癌中的表达降低。TMSB4Y表达低的喉癌患者相对于TMSB4Y表达高的患者预后更差。TMSB4Y逆转了miR-183对喉癌细胞恶性行为(包括细胞增殖、成集落能力、侵袭和迁移)的促进作用。miR-183的过表达通过抑制TMSB4Y的表达抑制细胞黏附。总体而言,所有结果表明,miR-183作为喉癌中的一种致癌分子,可能通过靶向TMSB4Y用于预测喉癌患者的预后。